Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112983 · ClinicalTrials.gov registry record · Phase 3
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
A Phase 3 study of Leukemia, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00112983 is a Phase 3 study of Leukemia that has completed, run by Jonsson Comprehensive Cancer Center. The trial reports 1 study location across 1 state.
The verdict
NCT00112983, a Phase 3 study of Leukemia, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eculizumab may prevent leukemia and stop the destruction of red blood cells in patients with paroxysmal nocturnal hemoglobinuria. PURPOSE: This randomized phase III trial is studying how well eculizumab works in treating patients with paroxysmal nocturnal hemoglobinuria.
Conditions Studied
Interventions
- BIOLOGICAL eculizumab
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-11 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112983
The ClinicalTrials.gov registry entry for NCT00112983 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which eculizumab is the first listed.
NCT00112983 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00112983 about?
NCT00112983 is a clinical study titled "Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eculizumab may prevent leukemia and stop the destruction of red blood cells in patients with paroxysmal nocturnal hemoglobinuria. PURPOSE: This randomized phase III trial is study...
What is the current status of trial NCT00112983?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-11. Estimated completion is 2005-06.
What conditions does trial NCT00112983 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00112983?
The interventions under investigation include: eculizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00112983?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00112983 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
-
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.